Event: VJVirtual

0:04:36

RUXOLITINIB (JAKAVI) Mechanism of action. Pharmacology. JAK2 mutation

0:00:40

VJ Loop DJ Club Visual Opener Stage Background Animation Visualizer Type Beat Artwork '314'

0:00:40

VJ Loop DJ Club Visual Opener Stage Background Animation Visualizer Type Beat Artwork '315'

0:00:40

VJ Loop DJ Club Visual Opener Stage Background Animation Visualizer Type Beat Artwork '316'

0:07:02

PROTEOSOME INHIBITORS Mechanism of Action. Pharmacology. Bortezomib, Ixazomib. Myeloma treatment.

0:03:30

Clinical value of event-free survival in AML

0:03:20

Phase I trial of a BCMA-CD3 bispecific antibody in R/R myeloma

0:02:43

Gemtuzumab ozogamicin in frontline AML therapy

0:02:59

Spectroscopic techniques for non-invasive diagnosis of Alzheimer’s disease

0:02:51

Bomedemstat for high-risk myelofibrosis

0:01:56

5-year follow up results of long-term use of ropeginterferon alfa-2b in polycythemia vera

0:01:17

Are MS patients at increased risk for developing cancer?

0:03:42

Isavuconazole: primary anti-fungal prophylaxis in AML and MDS

0:05:00

Diagnosing and treating AL amyloidosis: a 2020 update from Dr Morie Gertz

0:01:41

The impact of germline mutations on AML managment

0:01:36

Gait & dementia: tool to aid clinical decision-making and diagnosis

0:00:56

Immune-response in Alzheimer's disease

0:01:17

NK-CAR immunotherapy: the next steps

0:00:59

The current challenges facing high-risk MDS treatment

0:01:35

FIGHT: bemarituzumab + mFOLFOX6 in first-line advanced gastric cancer

0:03:41

Cell-free DNA for multi-cancer detection

0:02:57

Anti-cytokine receptor antibodies: potential treatment options for COVID-19?

0:01:55

MGUS progression to overt myeloma: the tumor microenvironment